

DOCKET NO.: CACO-0045



GPU 165 & A WD
Box 591
PATENT

RECEIVED

DEC 21 1999

TECH CENTER 1600/290C
RECEIVED

DEC 16 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:
Antoniou et al.

Serial No.: 09/247,054

Group Art Unit: 1632

TECH CENTER 1600/290C

Filing Date: February 9, 1999

Examiner: A. Baker

For: Self-Replicating Episomal Expression Vectors Conferring Tissue-Specific Gene
Expression

DATE OF DEPOSIT: December 9, 1999

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, DC 20231.

Doreen Yatko Trujillo
TYPED NAME: Doreen Yatko Trujillo
REGISTRATION NO.: 35,719

Box NON-FEE

SEQUENCE

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- A Preliminary Amendment.
- An Amendment Responsive to the Office Action dated July 9, 1999.
- An Amendment Supplemental to the Paper filed _____.
- Other: _____.

- Small entity status of this application under 37 C.F.R. 1.9 and 1.27 was established in a previous submission.
- A Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.
- Substitute Pages _____ of the Specification are enclosed.
- An Abstract is enclosed.
- _____ Sheets of Proposed Corrected Drawings are enclosed.
- A Certified Copy of each of the following applications: _____ is enclosed.
- An Associate Power of Attorney is enclosed.
- Information Disclosure Statement.
- Attached Form 1449.
- A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- Appended Material as follows: _____
- Other Material as follows: Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; Response to Notice to Comply ; Statement to Support Filing and Submission; Sequence Listing pages 1-8; Sequence Listing in computer readable form .

FEE CALCULATION

- No Additional Fee is Due.

			SMALL ENTITY		NOT SMALL ENTITY		
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	Fee	RATE	Fee
TOTAL CLAIMS	23	26 (20 MINIMUM)	0	\$9 EACH	\$ -0-	\$18 EACH	\$
INDEP. CLAIMS	3	3 (3 MINIMUM)	0	\$39 EACH	\$ -0-	\$78 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$130	\$	\$260	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
<input checked="" type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$190	\$ 190	\$380	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$435	\$	\$870	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$680	\$	\$1360	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$925	\$	\$1850	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$ 190		\$

- A Check is Enclosed in the Foregoing Amount Due.
- Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of **July 9, 1999** to and through **December 9, 1999** comprising an extension of the shortened statutory period of **two (2) months**.
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit

account 23-3050. This sheet is provided in duplicate.

- The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- The Forgoing Amount Due for Filing this Paper.
- Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).


SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: *December 9, 1999*

Doreen Yatko Trujillo
Doreen Yatko Trujillo
Registration No. 35,719

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

DOCKET NO.: CACO-0045



HJA
Klaus
01-10-00
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Antoniou et al.

Serial No.: 09/247,054

Group Art Unit: 1632

Filing Date: February 9, 1999

Examiner: A. Baker

**For: Self-Replicating Episomal Expression Vectors Conferring Tissue-Specific
Gene Expression**

12/15/1999 MSHIFERA 00000047 09247054

01 FC:216

190.00 OP

DATE OF DEPOSIT: December 9, 1999
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE
INDICATED ABOVE AND IS ADDRESSED TO
APPLICATION PROCESSING DIVISION'S CUSTOMER
CORRECTION BRANCH, ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, DC 20231.

Doreen Yatko Trujillo
TYPED NAME: Doreen Yatko Trujillo
REGISTRATION NO.: 35,719

Assistant Commissioner for Patents
Washington DC 20231

AMENDMENT AND REQUEST FOR RECONSIDERATION

Pursuant to 37 C.F.R. § 1.115, please amend the above-identified application as follows.

In the specification:

Please insert the enclosed Sequence Listing at the end of the application as filed.

In the claims:

Please cancel claims 22 and 24, without prejudice.

Please amend the claims as follows:

1. (Amended) A self-replicating episomal DNA expression vector for expressing a

[Handwritten signatures and initials]